Sign up to our newsletter Subscribe
Understanding societal preferences for priority by disease severity in England & Wales
Performance-Based Risk Sharing in Health Care: Current Status
Performance-based risk sharing arrangements for prescription medicines and other treatments are attractive to payers because they promise to base what is paid for a treatment on whether/how well it actually works. Programmes typically include data collection and either implicitly or…
Share:
Performance-based risk sharing arrangements for prescription medicines and other treatments are attractive to payers because they promise to base what is paid for a treatment on whether/how well it actually works. Programmes typically include data collection and either implicitly or explicitly link pricing, reimbursement and/or revenue to what the data show.
Performance-based risk sharing arrangements for prescription medicines and other treatments are attractive to payers because they promise to base what is paid for a treatment on whether/how well it actually works. Programmes typically include data collection and either implicitly or explicitly link pricing, reimbursement and/or revenue to what the data show.
At the mid-year symposium of the International Society of Pharmacoepidemiology (ISPE), OHE’s Adrian Towse reviewed the challenges such approaches present and experience to date. Adrian and Lou Garrison (University of Washington) co-chair the current ISPOR Performance-Based Risk-Sharing Arrangements Good Practices Task Force which will publish its report in Value in Health this summer. They will be presenting a half-day short course on risk-sharing/performance-based arrangements for drugs and other medical products at the ISPOR annual meeting in May 2013.
Performance based risk sharing arrangements for prescription medicines from Office of Health Economics
Examples of other OHE research on this topic
Puig-Peiró, R., Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2011) Literature review on Patient Access Schemes, flexible pricing schemes and risk sharing agreements for medicines. Poster presented at the PPRI Conference 2011. Vienna. 29-30 September.
Towse, A. and Garrison, L.P. (2010) Can’t get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics. 28(2), 93-102.
Towse, A., Garrison, L. and Puig-Peiró, R. (2012) The use of pay-for-performance for drugs: Can it improve incentives for innovation? Occasional Paper. 12/01. London: Office of Health Economics.
